PRIM-TECH3R Preclinical in vitro Models for the Replacement, Reduction and Refinement of Mouse Models in Preclinical Studies (PRIM-TECH3R)
- Coordinator
- Infrafrontier Eric, Germany
- Runs
- 1 April 2025 to 31 March 2028
- Status
- Running
- EU funding
- €9.0m
- Total cost
- €9.0m
- Partners
- 20 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101188158
What the project is doing
In the project's own words, from its summary on CORDIS.
The use of mouse models in biomedical research has been pivotal in understanding human diseases due to their genetic and physiological similarities to humans. However, concerns on ethics and translatability have prompted a shift towards alternative methods such as complex in vitro models (CIVMs). PRIM-TECH3R addresses this shift by leveraging advanced technologies to develop reliable mouse and human CIVMs for preclinical studies, aiming to reduce and refine the use of animal models.
Through standardised protocols and robust validation procedures, the project will create state-of-the-art in vitro models from mouse disease models, complementing existing in vivo models. This initiative aligns with EU policy objectives and societal demands to address phasing out of animal testing in biomedical research. The project will establish a comprehensive repository of preclinical resources, ensure open access, and foster collaboration between research infrastructures and the biomedical industry.
Training programmes will equip personnel with the necessary skills to provide CIVMs to the research community. By achieving these objectives, PRIM-TECH3R aims to advance the state-of-the-art in research infrastructures, facilitate industrial exploitation, and contribute to transformative changes in biomedical research practices.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Infrafrontier Eric | Neuherberg | Germany | Coordinator |
| Biobanks and Biomolecular Resources Research Infrastructure Consortium (bbmri-Eric) | Graz | Austria | Participant |
| Veterinaermedizinische Universitaet Wien | Wien | Austria | Participant |
| Fyziologicky Ustav Akademie Ved Ceske Republiky Verejna Vyzkumna Instituce (vvi) | Praha 4 | Czechia | Participant |
| Ustav Molekularni Genetiky Av Cr V.v.i. | Praha 4 | Czechia | Participant |
| European Molecular Biology Laboratory | Heidelberg | Germany | Third party |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Biomedcode Ellas Anonimi Eteria Epistimonikis Kai Texnologikis Erevnas Kai Emborikis Ekmetallefsis Epharmogon Iatrikis | Vari | Greece | Participant |
| Euro-Bioimaging Eric | Turku | Finland | Participant |
| Finnadvance Oy | Helsinki | Finland | Participant |
| Oulun Yliopisto | Oulu | Finland | Participant |
| Centre Europeen De Recherche En Biologie Et En Medecine | Illkirch Cedex | France | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Third party |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Karolinska Institutet | Stockholm | Sweden | Associatedpartner |
| United Kingdom Research and Innovation | Swindon | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI